论文部分内容阅读
目的研究Bcl-2蛋白、P53蛋白、细胞周期蛋白D1在B细胞淋巴瘤中的表达及临床意义。方法选取2010年1月至2015年8月在本院诊治的30例B细胞淋巴瘤患者资料,选取同期治疗的20例淋巴结反应性增生(RH)进行对照。用组织芯片技术对入选患者制备高通量样本,用免疫组织化学SP方法对采集标本的Bcl-2蛋白、P53蛋白、细胞周期蛋白D1(Cyclin D1)水平进行检测,分析Bcl-2、P53、Cyclin D1在B细胞淋巴瘤患者中的表达。结果不同类型的B细胞淋巴瘤患者的Bcl-2、P53、Cyclin D1表达不尽相同。Bcl-2:在弥漫性大B细胞淋巴瘤(DLBCL)、滤泡性淋巴瘤(FL)、小淋巴细胞淋巴瘤(SLL)、黏膜相关淋巴组织结外边缘带淋巴瘤(MALT)以及套细胞淋巴瘤(MCL)的阳性率分别为64.3%,50.0%,100.0%,50.0%,100.0%,阳性率显著高于RH 20%(P<0.05)。P53:在DLBCL、FL、SLL、MALT阳性率分别为57.1%,50.0%,33.3%,50.0%,且DLBCL、FL阳性率,显著高于RH的30%(P<0.05)。Cyclin D1:仅在MCL中表达为100%,显著高于RH(P<0.05)。结论 B细胞淋巴瘤与Bcl-2、P53协同表达途径及Cyclin D1水平异常存在紧密联系。
Objective To study the expression of Bcl-2 protein, P53 protein and cyclin D1 in B-cell lymphoma and its clinical significance. Methods The data of 30 patients with B-cell lymphoma diagnosed and treated in our hospital from January 2010 to August 2015 were selected. Twenty patients with reactive lymph node reactive hyperplasia (RH) were enrolled in this study. Tissue microarray was used to prepare high-throughput samples of selected patients. The levels of Bcl-2 protein, P53 protein and Cyclin D1 were detected by immunohistochemical SP method. The expressions of Bcl-2, P53, Expression of Cyclin D1 in B Cell Lymphoma Patients. Results The expressions of Bcl-2, P53 and Cyclin D1 in different types of B-cell lymphoma were different. Bcl-2: Apoptosis in diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), small lymphocytic lymphoma (SLL), extranodular lymphoma (MALT) associated with mucosa associated lymphoid tissue and mantle cells The positive rates of lymphoma (MCL) were 64.3%, 50.0%, 100.0%, 50.0% and 100.0%, respectively. The positive rate of MCL was significantly higher than that of RH 20% (P <0.05). P53: The positive rates of MALT in DLBCL, FL, SLL and MALT were 57.1%, 50.0%, 33.3% and 50.0% respectively, and the positive rates of DLBCL and FL were significantly higher than that of RH (30%, P <0.05). Cyclin D1: expressed only in MCL as 100%, significantly higher than RH (P <0.05). Conclusion B cell lymphomas have a close relationship with the expression of Bcl-2 and P53 and the abnormal Cyclin D1 levels.